Clinical Trial
Lumbrokinase for Long COVID, Post-treatment Lyme disease, and ME/CFS
The purpose of this study is to test if the dietary supplement lumbrokinase may have an effect on the overall symptom burden of several chronic illnesses: Long COVID, chronic Lyme (post-treatment Lyme disease syndrome), and Myalgic Encephalomyelitis (chronic fatigue syndrome).
Is this a virtual opportunity?
Yes! This is a decentralized opportunity — people located anywhere in the USA may receive study materials by mail and attend virtual study visits.
What are the location requirements?
You must be located in the USA.
Will there be in-person visits? If so, how many?
For those located in or near NYC and able to travel to the clinic, there will be 4 in-person visits. For those participating virtually, there will be 4 virtual check-ins.
Where is the study located?
5 East 98th Street, New York, New York, USA.
What is the length of participation?
The length of participation is 12 weeks.
What health qualifications are there to participate?
Long COVID (required proof of COVID infection which caused Long COVID)
Post-Treatment Lyme Disease Syndrome (required proof of Borrelia infection - we recommend iGeneX FISH testing)
ME/CFS (diagnosed pre-2020)
What kinds of tasks are associated with participation?
In-person participants will receive blood draws, EndoPat testing, surveys, and physical assessments.